Total
0
Shares
Source: Algernon Pharmaceuticals.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has confirmed that DMT increased neuron growth by 40 per cent in a preclinical study
  • The growth was achieved with a sub-hallucinogenic dose
  • Algernon’s clinical research program is focused on DMT as a treatment for stroke
  • Algernon investigates already approved drugs and naturally occurring compounds for new applications
  • Algernon Pharmaceuticals (AGN) is unchanged trading at $0.10 per share

Algernon Pharmaceuticals (AGN) has confirmed that DMT increased neuron growth by 40 per cent in a preclinical study.

The growth was achieved with a sub-hallucinogenic dose of 30 nM DMT. Significant growth was also observed at concentrations as low as 100 picomolar.

This initial data set will provide information on the dose and duration of infusion needed to achieve maximal cortical neurite outgrowth.

The second data set will focus on the duration of treatment time ranging from 1 to 72 hours and is expected to be completed by the end of October 2021.

The overall purpose of these studies is to optimize DMT’s neuroplastic effects without triggering hallucinations.

Algernon’s clinical research program is focused on DMT as a treatment for stroke.

Professor David Olson of the University of California, Davis was the first to investigate the decoupling of DMT’s psychedelic effects from its therapeutic effects.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, stated,

“We are very excited to have now independently confirmed with our own study that DMT is active in stimulating neuroplasticity. It is also vital to have shown that this activity in the neurons can be achieved with a sub-hallucinogenic dose and with only 1 hour of exposure, a dramatically shorter period when compared to Olson’s study. Things are moving along very quickly, and we are looking forward to the final data set from this preclinical study and starting our Phase 1 human study as soon as possible.”

Algernon is a drug repurposing company that investigates already approved drugs and naturally occurring compounds for new applications.

Algernon Pharmaceuticals (AGN) is unchanged trading at $0.10 per share as of 12:23 pm ET.

More From The Market Herald

" BioVaxys (CSE:BIOV) files patent for pan-sarbecovirus vaccine

BioVaxys Technology (BIOV) has filed a provisional patent application for its viral antigen vaccine platform.

" Datametrex (TSXV:DM) launches smartphone health app

Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app.
Avicanna Inc - CEO, Aras Azadian.

" Avicanna (TSX:AVCN) closes private placement

Avicanna (AVCN) has closed a non-brokered private placement for gross proceeds of approximately $3.9 million.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.